Coverage at a glance
| Indication | Coverage |
|---|---|
| Type 2 diabetes | Covered with prior authorization |
Plan type: Commercial non-Medicare. Each indication below lists the BMI and clinical thresholds, the prior-authorization documentation, and the published policy it comes from.
This varies by plan. Self-funded employer plans can adjust the formulary tier and prior authorization rules, so the exact step and quantity terms can vary by employer.
Coverage by indication
| Step therapy | Metformin inadequate response, intolerance, or contraindication is one qualifying path; documented alternatives include combination therapy with an A1C of 7.5 percent or higher, established cardiovascular disease, or chronic kidney disease. |
What the prior authorization needs:
- Documented type 2 diabetes diagnosis: A1C 6.5 percent or higher, fasting plasma glucose 126 mg/dL or higher, 2-hour OGTT plasma glucose 200 mg/dL or higher, or hyperglycemia symptoms with a random plasma glucose 200 mg/dL or higher (documentation required)
- For initial approval, patient has not already been on a stable GLP-1 or GIP/GLP-1 maintenance dose for at least 3 months
- One qualifying factor: inadequate response, intolerance, or contraindication to metformin; OR combination therapy with an A1C of 7.5 percent or higher; OR established cardiovascular disease; OR chronic kidney disease
- Quantity limit: one prefilled pen (3 mL) per 21 to 25 days for once-weekly dosing
- Prior authorization required; approval duration 12 months
Policy 2439-C. Source: Antidiabetic GLP-1, GIP-GLP-1 Agonist PA with Limit 2439-C P05-2025 v4. Official payer formulary / PA policy. Verified August 27, 2026.
What to do next
If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list then have your prescriber submit it. Plans that approve reassess at renewal, so know your long-term maintenance dose before you start.
- Browse the prior-authorization letter library for a template that matches your plan and indication.
- Read the full coverage picture, denial reasons, and the four appeal pathways at GLP-1 insurance coverage.
- If the prior-authorization request is denied, the appeal letter library has templates by denial reason, covering peer-to-peer review, Level 1 and Level 2 internal appeal, and external review.
- Call the number on your insurance card and ask whether your specific plan includes the weight-management drug benefit before you submit.
- If your plan does not cover the indication you need, compare cash prices in the cost guide or check whether a clinical trial near you fits. Neither one goes through your insurer. Clinical trials cost nothing and many pay you for your time. Some participants get a placebo, decided at random.
What it costs without insurance
The programs below bill you directly. Prices checked every Monday.
Frequently asked questions
Does Aetna cover Ozempic?
Aetna covers Ozempic for type 2 diabetes, but its pharmacy benefit manager, CVS Caremark, requires prior authorization under policy 2439-C. Approval needs a documented type 2 diabetes diagnosis (for example an A1C of 6.5 percent or higher) plus one qualifying factor, such as an inadequate response to or intolerance of metformin, combination therapy with an A1C of 7.5 percent or higher, established cardiovascular disease, or chronic kidney disease. A once-weekly quantity limit of one pen per fill applies, and an approval lasts 12 months. Ozempic is not covered for weight loss; that indication belongs to Wegovy, which is the same semaglutide at a higher dose. This reflects the published policy verified August 2026.
What does Aetna require to approve Ozempic?
For type 2 diabetes: Metformin inadequate response, intolerance, or contraindication is one qualifying path; documented alternatives include combination therapy with an A1C of 7.5 percent or higher, established cardiovascular disease, or chronic kidney disease.
Why might Aetna deny Ozempic even if I meet the criteria?
Self-funded employer plans can adjust the formulary tier and prior authorization rules, so the exact step and quantity terms can vary by employer.
Coverage for other payers
See the full payer coverage index for every plan we have sourced.
How we built this page
Each page is built from a published payer policy document, government statute, or independent formulary analysis (KFF). Every indication row carries the source URL and the date we verified it. Where a payer's policy PDF was confirmed at its public URL but served as an unreadable binary, the policy number and coverage framework were cross-checked against secondary sources; those rows are marked lower confidence. Commercial coverage often depends on whether an employer elected the weight-management benefit. Those rows say varies by plan rather than a flat yes.
This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.
